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Abstract
This paper covers several pathogenic theories of Parkinson’s disease (PD); the physiology and biological pathways involved .  This 
includes a mitochondrial DNA (mtDNA) route, a nuclear DNA route, and other hypotheses about idiopathic PD .  The subsequent 
discussion of PD symptoms utilizes a neurological perspective, analyzing the neuroanatomical systems involved, and how they 
are treated .  This includes medications and surgical techniques that are employed in an effort to manage symptomatology and 
increase health-related quality of life .
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Introduction
Neurodegenerative diseases are characterized by pro-
gressive and selective loss of anatomically or physiologi-
cally related neuron systems.  The clinical syndromes as-
sociated with particular neuroanatomical patterns of cell 
loss and dysfunction are typically categorized by whether 
they initially affect cognition, movement coordination, 
sensation, vision, or autonomic control.  Typical examples 
of such neurodegenerative diseases include Alzheimer’s 
disease, Huntington’s and Parkinson’s disease (Lezi and 
Swedlow, 2012).  Cholinergic neurons are implicated in 
Alzheimer’s, and a degeneration of neurons in the do-
paminergic system is responsible for Parkinson’s disease. 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease, afflicting 1-3% of the 65+ age 
group.  It is characterized by accumulation of abnormal 
protein (Lewy bodies) in the dopaminergic neurons of 
the substantia nigra pars compacta (SNc) and their 
subsequent degeneration.  These are abnormal circular 
structures with a dense protein core and a halo of ra-
diating fibers.  They consist of aggregations of misfolded 
α-synuclein along with neurofilaments and other pro-
teins.  This neuron loss leads to a difficulty controlling 
movement.  The motor symptoms include bradykinesia, 
postural instability, muscle rigidity, and tremors.  Some 
of the non-motor symptoms (NMS) include depression, 
insomnia, anxiety, apathy, psychosis, incomplete bowel 
emptying, impulse control disorders, and dementia. 
The disease involves progressive degeneration which, 
as of now, cannot be stopped or slowed.  There are effec-
tive medications that can be used to compensate for do-
paminergic neuron loss, such as L-dopa, and other types 
of dopamine (DA) agonists.  These work by increasing the 
potency of the surviving neurons and synapses, but only 
temporarily.  Eventually, the disease will wipe out these 
pathways entirely. Furthermore, the disease spreads to 
other regions of the brain and causes other symptoms. 
For example, when neurodegeneration spreads to cho-
linergic neuronal pathways, the patient will start to show 
signs of dementia.  For now, treatment options are limited 
to symptom management.  This paper discusses some of 
those treatment options, but first it is important to con-
sider the PD pathogenesis and symptom origin. Then, this 
paper will delve into the innovations available for those 
suffering from PD, and explain how they work. 
Mitochondrial Pathogenesis of PD
Mitochondria are the site of bioenergetics and biosyn-
thesis in the cell.  Hans Krebs, for whom the tricarboxylic 
acid (TCA) cycle is named, said of his discovery “in some 
micro-organisms the cycle primarily supplies intermedi-
ates rather than energy, whilst in the animal and most 
other organisms it supplies both energy and intermedi-
ates”.  The energy supplied by the TCA cycle is in the 
form of NADH and FADH2, whose electrons are then 
fed into the electron transport chain (ETC) to pump pro-
tons into the inner membrane space of the mitochondri-
on creating a pH gradient.  This gradient is then used to 
power the conversion of ADP into ATP.  A high ATP/ADP 
ratio is required to catalyze the chemical reactions that 
comprise many of the metabolic operations of the cell. 
Additionally, many of the building blocks that a cell 
needs to form its assortment of macromolecules are 
made using the intermediates of glycolysis and the cit-
ric acid cycle.  For example, about half of the 20 amino 
acids found in human protein can be synthesized in vivo 
through the modification of Krebs Cycle intermediates 
(Reece et al., 2011). Also fatty acids are synthesized from 
acetyl CoA, which is produced by the conversion of py-
ruvate within the mitochondria.  It is important to note 
that when the mitochondria are employed in an anabolic 
capacity (the building of larger molecules and utilization 
of TCA intermediates) they are no longer producing ATP 
but consuming this molecule.
There is some evidence implicating mutations in mi-
tochondrial DNA (mtDNA) or nuclear genes coding for 
mitochondrial protein in the pathogenesis of PD.  Several 
research teams working in 1989 reported a reduction of 
activity of Complex 1 of the ETC in the substantia nigra 
in patients with idiopathic PD (Lezi and Swedlow, 2012). 
This study was based on reports of healthy individuals de-
veloping Parkinson’s like symptoms after consuming the 
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP).  It was determined that the active metabolite 
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of MPTP is taken up by the cell via the dopamine trans-
porters, allowing them to cluster and wreak havoc in do-
paminergic neurons.  This particular metabolite inhibits 
Complex 1 of the electron transport chain, which was 
assumed to have led to the exhibition of Parkinson’s 
symptomatology. 
The suggested hypothesis is that mutations within 
genes coding for mitochondrial DNA or in mtDNA it-
self, specifically Complex 1 genes, can be implicated in PD 
pathogenesis.  Complex 1 contains 46 protein subunits, 
seven of which are encoded by mtDNA.  A mutation 
causing a decrease in Complex 1 activity would lead to 
a drop in ATP production and increased oxidative stress 
and cellular deterioration from the accumulation of free 
radicals (Lezi and Swedlow, 2012). 
It is unclear why dopaminergic neurons of the substan-
tia nigra would be uniquely susceptible.  However, what 
is clear is that the failure of these nigral dopaminergic 
systems are responsible for the symptoms of PD.  Based 
on the research done on mitochondrial involvement in 
dopaminergic deterioration in PD or induced PD symp-
toms, there is sufficient justification to investigate treat-
ment options targeting the mitochondria, which work to 
encourage proper functionality and cellular respiration 
(Lezi and Swedlow, 2012). 
α-synuclein and PD
Researchers have discovered that a mutation on chromo-
some 4 will produce PD (Polymeropoulos, et al., 1996), 
the gene that codes for α-synuclein.  This protein can be 
found in the axon terminals and is involved in synaptic 
transmission in dopaminergic neurons.  A mutation in this 
gene can result in a mistranslated and subsequently mis-
folded α-synuclein that is toxic to the cell.  These proteins 
group together in large aggregates called Lewy bodies 
which devastate normal cell function.
The majority of PD cases are sporadic.  They occur 
without any family history or hereditary basis for the dis-
order.  Some researchers suggest that an unknown toxin 
in the environment, faulty metabolism, or infection may 
be the culprit in these cases.  There are two insecticides 
that are known to cause PD, and presumably there may 
be more.  These toxins might interfere with mitochon-
drial signaling which, when impaired, could cause these 
aggregations of α-synuclein to resist degradation and per-
sist in the cytoplasm of nigral neuron systems.
Symptoms and Their Physiology
The loss of the brain’s most important dopamine sup-
pliers, the neurons of the SNc, leads to a variety of 
symptoms.  Resultant motor symptoms include tremors, 
muscle rigidity, bradykinesia, and postural imbalance - 
the symptoms that normally come to mind when peo-
ple think of Parkinson’s disease.  These symptoms arise 
directly from neuron loss in the motor regulation cen-
ters of the brain (Carlson & Birkett, 2017).  Additionally, 
many other neural pathways are affected by damage to 
the substantia nigra, such as the areas where these do-
paminergic neurons project, namely, the basal ganglia and 
the nucleus accumbens.  The basal ganglia are involved in 
controlling movement, but they also project to the frontal 
lobes of the brain and play a role in thinking and execu-
tive functions.  The nucleus accumbens has been linked 
to behavioral regulation, Thus, dopamine irregularities in 
this region can lead to changes in personality (Carlson & 
Birkett, 2017).
The causes for some of the non-motor symptoms are 
pretty clear, while others are more complicated and de-
batable.  Some symptoms arise directly from a decrease in 
dopamine (DA) production in the substantia nigra.  Other 
symptoms are a result of the DA agonist prescribed to 
the patient.  This might be due to the dramatic fluctua-
tions of DA in the brain owing to the medication sched-
ule.  Still other symptoms might be due to an increased 
potency in certain dopaminergic systems that have not 
been impacted by the disease.  When the patient takes 
L-dopa, these functioning dopaminergic neurons release 
too much DA.  This DA flood triggers a deficit in exec-
utive functions, according to the Dopamine Overdose 
Hypothesis (Dirnberger & Jahanshahi, 2013).  
Other symptoms result from unrelated pathways that 
happen to be proximal to damaged areas of the brain. 
Lewy bodies are often present in the dopaminergic neu-
rons of those with PD.  Many of these misfolded proteins 
that cause neurodegeneration can be transferred from 
cell to cell (Lee, et al., 2011).  This perhaps explains how 
the serotonergic, noradrenergic, and cholinergic systems 
become impacted in later stages of PD. 
Treatments
Since there is no cure for PD, the standard treatment is 
symptom management, by way of DA agonists.  The most 
common one in use is L-dopa, a neurotransmitter (NT) 
precursor which dopaminergic neurons can convert to 
dopamine.  This maximizes its potency through increas-
ing the amount of NT present in the synaptic cleft with 
each firing of the surviving neurons.  When other systems 
are involved in degeneration, such as the serotonergic, 
noradrenergic, and cholinergic systems, agonists for each 
of those NTs can be used to alleviate symptoms.  Some 
symptoms arise from too much dopamine in the healthier 
dopamine pathways, or fluctuations of dopamine based 
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on medication schedule (Dirnberger & Jahanshahi, 2013). 
These symptoms can be treated by using different DA 
agonists at different times and by changing doses.  The 
reason for the variety of dopamine agonists is to reduce 
fluctuations and mitigate some symptoms that may arise 
from any one particular DA agonist.
Another possible medication is Deprenyl, which was 
initially discovered to be effective after the outbreak of 
PD among users of the drug MPTP.  The idea behind it 
was to inhibit the activity of the monoamine oxidase-B 
enzyme and hopefully block the toxins from attacking and 
damaging the neurons.  Although the drug does alleviate 
symptoms, it does not reverse, stop, or slow the progres-
sion of disease (Williams, 2010).
One surgical technique involved the grafting of nigral 
neurons taken from aborted fetuses, to replace the ones 
lost to PD.  This was shown to work particularly well in 
patients who responded well to L-dopa earlier in the dis-
ease.  Presumably, these patients had enough healthy neu-
rons in the basal ganglia to process and secrete dopamine, 
whether intrinsic or from grafted tissue.  Unfortunately, 
many of these patients later developed debilitating dys-
kinesias and the surgery is no longer recommended 
(Olanow, et al., 2003).
Upon closer inspection, it seemed as though the fetal 
tissue had been successful in making the proper con-
nections with the basal ganglia.  However, with time, the 
aggregate α-synuclein deposits made their way from dam-
aged host cells to transplanted healthy cells (Kordower, et 
al., 2011).  Any misfolded proteins responsible for neuro-
degeneration can be transferred from cell to a cell close 
by (Lee, et al., 2011).  It seems that adding healthy cells to 
the basal ganglia will not work unless a way is found to 
prevent the α-synuclein from aggregating in the first place 
and spreading to neighboring cells.
GPi and STN Related Therapies
The main output of the basal ganglia is from the internal 
division of the globus pallidus (GPi) and it is inhibitory. 
Researchers found that whenever there is a decrease of 
activity to the putamen and the caudate nucleus (which 
is a byproduct of SNc neuron death due to PD) there is 
an increase in inhibitory signaling from GPi to the motor 
cortex.  It was suggested that destroying this area might 
help mitigate some of the motor symptoms.  This strat-
egy worked well and was a pretty good option but the 
surgery was quite risky.  The optic tract is located quite 
proximal to the GPi and some patients were blinded by 
the surgery.  Due to advancements in imaging and surgical 
techniques, this option has become safer, and can be rec-
ommended for younger patients who no longer respond 
to L-dopa.  Neurosurgeons can get similar results by 
destroying the subthalamic nucleus (STN) (Guridi, J & 
Obeso, 2001), which has an excitatory effect on GPi. 
Another option that is growing in popularity due to re-
fined surgical techniques is deep brain stimulation (DBS). 
Here, instead of destroying GPi and STN, microelectrodes 
are placed in these regions for the patient to stimulate as 
needed.  This technique is as effective as brain lesions in 
suppressing tremors but with fewer risks (Esselink, et al., 
2009).  DBS might also be effective against depression and 
cognitive impairment in PD. 
Conclusion
There are some innovative techniques for treating PD 
and a lot of promising research on the horizon.  Through 
pursuit of the various pathogenesis hypotheses, we are 
getting closer to understanding the mechanisms of neu-
rodegeneration.  This information is crucial to finding a 
strategy to reverse the disease progression.  In the mean-
time, there are many interventions available to those 
suffering from PD that can dramatically improve quality 
of life.  It is a devastating diagnosis to receive but there 
is plenty of hope.  It is crucial that those diagnosed with 
PD are taught about the potential symptoms and how 
they can be treated.  Specifically the many non-motor 
symptoms not directly caused by degeneration of do-
paminergic neurons.  Treatment of these symptoms is 
achieved through some of the more creative and inno-
vative treatments discussed in this paper.  These non-mo-
tor symptoms are less known by the patients but were 
found to be more injurious to the patient’s quality of life 
than the classic symptoms (Duncan, et al., 2013).  As the 
research into PD genesis, pathways and mechanisms de-
velops, more therapies are being discovered to treat this 
complex and multifaceted disease.
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